| 2025年中报 | 2024年年报 | 2024年中报 | |
|---|---|---|---|
| 营业收入(元) | |||
| 糖尿病类(元) | - | 474,057,188.28 | 235,235,726.65 |
| 心血管类(元) | - | 84,210,323.29 | 69,554,279.27 |
| 药品推广服务(元) | -898,044.98 | - | - |
| 药品销售(元) | 310,538,359.81 | - | - |
| 其他(元) | 1,805,268.47 | 93,616,395.03 | 47,194,803.11 |
| 营业成本(元) | |||
| 糖尿病类(元) | - | 71,883,836.91 | 31,192,973.70 |
| 心血管类(元) | - | 76,508,989.59 | 59,402,840.72 |
| 药品推广服务(元) | - | - | - |
| 药品销售(元) | 58,965,343.53 | - | - |
| 其他(元) | - | 56,860,110.73 | 28,090,715.07 |
| 毛利(元) | |||
| 糖尿病类(元) | - | 402,173,351.37 | 204,042,752.95 |
| 心血管类(元) | - | 7,701,333.70 | 10,151,438.55 |
| 药品推广服务(元) | - | - | - |
| 药品销售(元) | 251,573,016.28 | - | - |
| 其他(元) | - | 36,756,284.30 | 19,104,088.04 |
| 毛利率(%) | |||
| 糖尿病类(%) | - | 84.84 | 86.74 |
| 心血管类(%) | - | 9.15 | 14.59 |
| 药品推广服务(%) | - | - | - |
| 药品销售(%) | 81.01 | - | - |
| 其他(%) | - | 39.26 | 40.48 |
| 收入构成(%) | |||
| 糖尿病类(%) | - | 72.72 | 66.83 |
| 心血管类(%) | - | 12.92 | 19.76 |
| 药品推广服务(%) | -0.29 | - | - |
| 药品销售(%) | 99.71 | - | - |
| 其他(%) | 0.58 | 14.36 | 13.41 |
| 毛利构成(%) | |||
| 糖尿病类(%) | - | 90.05 | 87.46 |
| 心血管类(%) | - | 1.72 | 4.35 |
| 药品推广服务(%) | 0.00 | - | - |
| 药品销售(%) | 100.00 | - | - |
| 其他(%) | 0.00 | 8.23 | 8.19 |